Bausch + Lomb Co. (NYSE: BLCO) Receives Consensus “Buy Moderate” Recommendation From Brokerages

Bausch + Lomb Co. (NYSE: BLCO – Get Rating) shares have earned an average rating of “moderate buy” from the twelve rating agencies that currently cover the company, reports. Four investment analysts rated the stock with a hold recommendation and eight gave the company a buy recommendation. The 12-month average price target among brokerages that have reported on the stock over the past year is $24.18.

Several research analysts have recently released reports on BLCO shares. Guggenheim launched a hedge on Bausch + Lomb shares in a Tuesday, May 31 research note. They set a “buy” rating and a price target of $24.00 on the stock. Bank of America launched coverage on Bausch + Lomb in a research report on Tuesday, May 31. They set a “buy” rating on the stock. Cowen assumed coverage for Bausch + Lomb in a Wednesday, May 11 report. They issued an “outperform” rating and a price target of $35.00 for the company. Jefferies Financial Group began covering Bausch + Lomb in a report on Tuesday, May 31. They set a “buy” rating and a target price of $25.00 on the stock. Finally, Morgan Stanley cut its price target on Bausch + Lomb shares from $22.00 to $20.00 and set an “equal weight” rating for the company in a Thursday, June 9 report.

(A d)

What is the most productive stock you have ever owned? Dividends from these stocks have grown so rapidly over the years that they now earn us an average of 26%!

When you start getting paid 26% on your money, your financial troubles tend to evaporate.

BLCO shares opened at $15.85 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.57 and a debt ratio of 0.31. Bausch + Lomb has a 52-week low of $13.17 and a 52-week high of $20.20.

About Bausch + Lomb (Get a rating)

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Healthcare, Ophthalmic Pharmaceuticals and Surgery. The Vision Care/Consumer Health Care segment provides contact lenses that cover the spectrum of wearing modalities, including daily and frequently replaced disposable contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that treat a variety of conditions, including eye allergies, conjunctivitis, and dry eyes.

See also

Analyst Recommendations for Bausch + Lomb (NYSE: BLCO)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Bausch + Lomb right now?

Before you consider Bausch + Lomb, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Bausch + Lomb didn’t make the list.

While Bausch + Lomb currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

About Marion Alexander

Check Also

JJV Contact Lens Recycling Program

The contact lens recycling system we use is one facilitated by Johnson & Johnson Vision …